Clinical Trials Logo

Filter by:
NCT ID: NCT00173901 Active, not recruiting - Infection Clinical Trials

Adverse Drug Reactions of Different Brands of Ceftazidime Injection

Start date: March 2001
Phase: Phase 4
Study type: Interventional

The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.

NCT ID: NCT00173524 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)

Start date: September 2005
Phase: Phase 4
Study type: Observational

The objective of this pharmacoeconomics (PE) study is to evaluate the cost- effectiveness analysis and cost-utility analysis of IRESSA® as first line treatment of NSCLC from the society perspective, based on resources and outcomes from patients who met the inclusion criteria for this naturalistic study comparing to existing first line platinum-based regimen chemotherapy.

NCT ID: NCT00173472 Active, not recruiting - Colorectal Cancer Clinical Trials

Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer

Start date: July 2002
Phase: Phase 3
Study type: Observational

The present project will follow our previous phaseⅡ study of FOLFOX regimens for the treatment of stage Ⅳ colorectal cancer. We will recruit at least 200 patients for this study. The selection of patients will be based on rigorous eligibility criteria. The patients will be allocated based on the expression of each molecular marker (MSI, TS, DPD, MVD and EGFR) and the implementation of chemotherapy. For example, in the examination for the clinical implications of EGFR, the patients will be classified into four groups: EGFR(+) chemotherapy(+); EGFR(+) chemotherapy(-); EGFR(-) chemotherapy(+); EGFR(-) chemotherapy(-). Base on the analysis of this 2×2 table, we will clarify the prognostic significance of a specific molecular marker is due to whether the specific molecular marker predicts biological invasiveness and/or chemosensitivity. We believe the present study will have the following significance: (1)To further clarify the mechanisms for the carcinogenesis and progression of CRC; (2)To facilitate the development of novel chemotherapeutic agents; and (3) To gain the experience for the practice of evidence-based medicine.

NCT ID: NCT00173212 Active, not recruiting - Endometriosis Clinical Trials

Proliferation of Endometrial Stromal Cells in Adenomyosis

Start date: September 2005
Phase: N/A
Study type: Observational

Adenomyosis refers to the presence of endometrial glands and stroma that is haphazardly deep within the myometrium. However, the etiology and pathologic mechanism responsible for adenomyosis are not yet very well known. Our previous results revealed that the expression of killer inhibitory receptors on natural killer cells was decreased in eutopic endometrium in women with adenomyosis. It implies that the formation of adenomyosis might be due to abnormal endometrial tissues, but not the aberrant local immunological dysfunction in myometrium. Our further investigation revealed that in vitro coculture of macrophages and endometrial stromal cells (ESCs) increase the expression of IL-6 mRNA in ESC, which might further enhance the proliferation of ESC and subsequently result in the formation of ectopic endometrial implants in adenomyosis. Abnormal cell proliferation has been generally found in the tumorigenesis, including the formation of endometriosis. Adenomyosis is considered to have a similar pathophysiology with endometriosis, and it must be interesting to examine whether there is abnormal cell proliferation in the eutopic endometrium of adenomyosis. Lipopolysaccharide (LPS) was found to promote proliferation of ESCs via induction of TNF-a and IL-8 expression, whereas IFN-g significantly inhibited ESCs proliferation. Therefore, whether abnormal cell proliferation occurs under the effects of LPS and IFN-g in the eutopic endometrium of adenomyosis needs further clarification. Adenomyosis preferentially affects women between the ages of 35 and 50 years, and the symptoms subside gradually after menopause. It is well known that there is a close conjunction between estrogen and adenomyosis. Estradiol (E2) was demonstrated to induce endometrial cell proliferation, whereas medroxyprogesterone (MPA) inhibited endometrial cell proliferation via antagonizing estrogenic effects. Experiments to investigate these steroid effects on ESC proliferation in vitro in the eutopic endometrium of adenomyosis are of clinical relevance. In this study, we try to collect endometrial tissues from women with and without adenomyosis, and then purify ESCs from endometrium. ESCs are cultured for 2 days with the supplement of LPS, IFN-gamma, Estradiol, MPA and Estradiol+MPA. Quantification of cell proliferation was done with Cell Proliferation Assay Kit and immunocytochemical detection of Ki-67, in an attempt to examine the cell proliferation of ESCs in women with adenomyosis.

NCT ID: NCT00172146 Active, not recruiting - Stroke Clinical Trials

Influences of Cane Use on Voluntary Forward Stepping Movement and Associated Attentional Demands in Hemiplegic Patients

Start date: August 2002
Phase: N/A
Study type: Observational

The purpose of this study was to examine the influence of cane use on the movement, kinetics, and associated attentional demands of performing a voluntary forward stepping movement in patients with stroke and age-matched healthy adults.

NCT ID: NCT00167076 Active, not recruiting - Stroke Clinical Trials

Clinical Applications and Evaluations of A Portable In-Shoe Plantar Pressure Monitoring and Biofeedback Gait System for Ambulation Training in Stroke Rehabilitation

Start date: August 1999
Phase: N/A
Study type: Observational

The purposes of this paper were to determine whether walking speed affected gait parameters and force impulse in patients with stroke or not, and if the changes varied in various foot regions.

NCT ID: NCT00167063 Active, not recruiting - Stroke Clinical Trials

Falls in Stroke Patients After Hospital Discharge: Prevalence and Risk Factors

Start date: August 1999
Phase: N/A
Study type: Observational

The purposes of this study are: (1) to investigate the incidence and causes of falls of stroke patients residing in Taipei City and Taipei county after their discharge from the National Taiwan University Hospital, (2) to investigate the relationship between clinical manifestations of stroke patients before their hospital discharge and their incidence of falls after hospital discharge, and (3) to identify the risk factors for stroke patients who frequently fall after hospital discharge.

NCT ID: NCT00166842 Active, not recruiting - Clinical trials for Kidney Transplantation

Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets

Start date: September 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to understand the pharmacokinetics of sirolimus tablets in different regimens in newly renal transplant patients, and the effect of dosage form conversion on the concentration of sirolimus in stable renal transplant patients. So that we can design a better tacrolimus or cyclosporine/sirolimus/steroid dose regimen for Taiwanese.

NCT ID: NCT00166816 Active, not recruiting - Clinical trials for Kidney Transplantation

The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients

Start date: March 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to understand the pharmacokinetic of sirolimus in different regimens, as well as the dose-level relationship of cyclosporine and tacrolimus, and design the most appropriate cyclosporine/sirolimus/steroid or tacrolimus/sirolimus/steroid dose regimen for Taiwanese.

NCT ID: NCT00162877 Active, not recruiting - Clinical trials for Peptic Ulcer With H. Pylori Infection

The Role of CYP2C19 on the Eradication of H. Pylori Infection:Implication of PK/PD Relationships

Start date: June 2004
Phase: N/A
Study type: Interventional

The objective of this trial is to find the rationale and the optimal dose and duration of regimen for the eradication of H. pylori infection using different proton pump inhibitors.